Lightpoint announces positive clinical trial data for SENSEI® in prostate cancer surgery at the Annual Congress of the European Association of Nuclear Medicine. SENSEI®  achieved 100% detection of sentinel lymph nodes in prostate cancer surgery and detected more sentinel nodes than a conventional gamma probe.

Dr Matthias Heck at the Technical University of Munich is the world's first surgeon to test SENSEI® in combination with PSMA in prostate cancer surgery. 

 Lightpoint and Telix agree strategic collaboration to explore how Lightpoint's innovative surgical devices and Telix's molecularly-targeted imaging agents can be used together for real-time intra-operative cancer detection.